🧠 Personalized Neoantigen Vaccines May Finally Crack Glioblastoma Immunotherapy
For decades, glioblastoma (GBM) has remained one of oncology’s greatest failures for immunotherapy.
Checkpoint inhibitors revolutionized melanoma and lung cancer.
CAR-T showed flashes of promise.
Peptide vaccines generated excitement.
But GBM kept winning.
Now a new Nature Cancer study may point toward a fundamentally different strategy: ➡️ highly personalized, broad-spectrum neoantigen vaccination.
In the GT-20 phase 1 trial, researchers developed individualized DNA vaccines encoding up to 40 patient-specific tumor neoantigens for newly diagnosed MGMT-unmethylated GBM — among the most treatment-resistant brain tumors.
This was not a “one antigen fits all” approach.
Each patient underwent: • multiregion tumor sequencing
• neoantigen prediction using pVAC-seq
• custom plasmid vaccine manufacturing
• intramuscular electroporation delivery
• IL-12 adjuvant stimulation
The goal was simple but ambitious:
Generate a sufficiently broad T cell response to overcome GBM heterogeneity and immune escape.
And remarkably, it worked biologically.
The vaccine induced: 🔥 expansion of tumor-reactive T cell clones
🔥 broad peripheral immune activation
🔥 durable antigen-specific responses
Most importantly, the therapy appeared capable of shifting GBM from an immunologically “cold” tumor toward a more inflamed immune state.
That matters enormously.
Many believe GBM immunotherapy failed not because checkpoints are irrelevant, but because there are too few pre-existing antitumor T cells for checkpoint blockade to rescue.
In other words: No priming → no checkpoint efficacy.
This platform may solve the priming problem first.
Clinical outcomes remain preliminary: • Median PFS: 8.5 months
• Median OS: 16.3 months
• 24-month survival: 33%
• One patient survived nearly 5 years
Importantly, this was:
Phase 1
Single-arm
n=9
So this is NOT proof of efficacy.
But mechanistically, these signals are unusually compelling for GBM.
Another critical point: the platform used DNA vaccines rather than peptide vaccines.
That enables: • larger neoantigen payloads
• scalable manufacturing
• iterative redesign
• broader epitope coverage
This could become especially powerful when combined with:
PD-1 blockade
Treg/myeloid suppression
oncolytic viruses
radiotherapy-induced antigen spreading
The broader implication extends beyond GBM.
This study reinforces an emerging principle in cancer immunotherapy:
The future may belong not to generic immune activation — but to precise, patient-specific neoantigen engineering.
In highly heterogeneous tumors, breadth may matter as much as intensity.
DOI: 10.1038/s43018-026-01163-w